Immune Thrombocytopenia

In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of the Bruton tyrosine kinase inhibitor rilzabrutinib in patients with immune thrombocytopenic purpura.

SAN DIEGO — Eltrombopag conferred a higher rate of durable platelet response in the absence of rescue treatments than standard first-line treatments for children with newly diagnosed immune thrombocytopenia, according to study results.

SAN DIEGO — Rilzabrutinib induced “fast” and “persistent” platelet count expansion for heavily treated individuals with immune thrombocytopenia, according to results of the randomized phase 3 LUNA 3 study.

Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.

SAN DIEGO — Rilzabrutinib treatment led to rapid, stable and durable platelet responses among patients with relapsed immune thrombocytopenia, according to data presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Efgartigimod demonstrated clinically significant improvement in platelet counts compared with placebo among adults with primary immune thrombocytopenia, results of the phase 3 ADVANCE IV trial showed.

Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.

Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves response and decreases the risk for refractory or relapsed disease, according to data.

Low platelet count and intracranial hemorrhage appeared associated with increased risk for death among hospitalized patients with COVID-19 vaccine-induced immune thrombocytopenia and thrombosis, according to study results.

The addition of mycophenolate to standard first-line steroid treatment appeared effective for patients with newly diagnosed immune thrombocytopenia, according to study results presented at the virtual ASH Annual Meeting and Exposition.